Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tolerability

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14,030 result(s) found for: Tolerability. Displaying page 8 of 702.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2006-003805-19 Sponsor Protocol Number: EFC5583 Start Date*: 2006-11-06
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: An eight-week, multinational, multicenter, randomized, double-blind, placebo-controlled study, with escitalopram as an active control, to evaluate the efficacy, safety and tolerability of a saredut...
    Medical condition: To evaluate the efficacy, safety and tolerability of a saredutant 100 mg dose once daily, in patients with generalized anxiety disorder.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001801-99 Sponsor Protocol Number: 333369EPY3004 Start Date*: 2007-08-13
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An open label study to evaluate the efficacy, safety and tolerability of RWJ333369 as adjunctive therapy in subjects with partial onset seizure
    Medical condition: Partial Onset Epilepsy Seizures
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-004363-34 Sponsor Protocol Number: MB 0704/1707/03 Start Date*: 2006-03-30
    Sponsor Name:VALEAS
    Full Title: Antibiotic therapy in children for the upper respiratory tract infections. Study of the ''tollerability profile'' of cefaclor and amoxicillin-clavulanate
    Medical condition: Pharyngitis, Pharyngotonsillitis or Sinusitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057868 Upper respiratory tract infection bacterial LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001885-41 Sponsor Protocol Number: DLX105-003-002-001 Start Date*: 2013-07-11
    Sponsor Name:Delenex Therapeutics AG
    Full Title: A multi-center, double-blinded, randomized, placebo-controlled, phase II study to evaluate the safety, tolerability and efficacy of a topical application of DLX105 onto lesional skin in patients wi...
    Medical condition: mild-to-moderate plaque-type psoriasis vulgaris 6 (PASI ≤15)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004454-34 Sponsor Protocol Number: NN8022-4181 Start Date*: 2017-09-13
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, double-blind, placebo-controlled trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of liraglutide in obese children aged 7 to 11 years
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002292-26 Sponsor Protocol Number: CLYS228X2201 Start Date*: 2018-02-05
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, controlled, evaluator-blinded, multicenter, study to evaluate LYS228 pharmacokinetics, clinical response, safety and tolerability in patients with complicated urinary tract infection
    Medical condition: complicated Urinary Tract Infection (cUTI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10054088 Urinary tract infection bacterial PT
    20.1 10021881 - Infections and infestations 10079982 Complicated lower urinary tract infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) GR (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003418-28 Sponsor Protocol Number: CLNA043X2201 Start Date*: 2017-04-18
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, placebo-controlled, patient and investigator blinded, single dose, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of intra-articular LNA043 in ...
    Medical condition: Acute cartilage injuries
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031161 Osteoarthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000650-10 Sponsor Protocol Number: LAS-213 Start Date*: 2020-02-12
    Sponsor Name:Octapharma
    Full Title: An open-label, multicenter, Post-Marketing Requirement study to investigate the safety and tolerability of octaplas™ in the management of pediatric patients who require therapeutic plasma exchange.
    Medical condition: Therapeutic plasma exchange
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005120-13 Sponsor Protocol Number: VR040/001 Start Date*: 2005-12-21
    Sponsor Name:Vectura Group plc
    Full Title: A clinic based, Phase IIa, randomised, double-blind, placebo-controlled, ascending dose, single centre study investigating the safety, tolerability, efficacy, and pharmacokinetics of VR040 in patie...
    Medical condition: Hypomobility (“off” or “freezing”) episodes associated with advanced Parkinson’s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005237-10 Sponsor Protocol Number: 176003 Start Date*: 2009-01-28
    Sponsor Name:NV Organon
    Full Title: A twenty-six weeks, open-label extension trial to evaluate safety and efficacy of Org 50081 in outpatients with chronic primary insomnia who completed clinical trial protocol 21106.
    Medical condition: Primary insomnia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036701 Primary insomnia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Prematurely Ended) DE (Completed) FR (Prematurely Ended) NL (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000895-25 Sponsor Protocol Number: V87P11 Start Date*: 2008-10-18
    Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG
    Full Title: A Phase II, Open-label, multi center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
    Medical condition: The present study is therefore designed to evaluate the immunogenicity, safety and tolerability of two doses of FLUAD-H5N1 vaccine containing A/H5N1/turkey/Turkey/05 administered 3 weeks apart in n...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-020681-16 Sponsor Protocol Number: LO-10-01 Start Date*: 2010-10-12
    Sponsor Name:Lunamed Operations AG
    Full Title: A PILOT STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND EFFICACY OF A DAILY DOSE OF 500MG. LU901 (4PHENYL-BUTYRATE, CONTROLLED RELEASE TABLETS) IN ADDITION TO STANDARD HORMONAL TREATMENT IN PATIE...
    Medical condition: Patients suffering from prostate carcinoma with progression under first line hormonal treatment. Patients entering the study should have a life expectancy prognosis of at least 6 months.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10007453 Carcinoma of the prostate metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004519-28 Sponsor Protocol Number: H573000-1307 Start Date*: 2013-12-20
    Sponsor Name:Almirall Hermal GmbH
    Full Title: A phase II trial to evaluate the anti-psoriatic efficacy and tolerability of tazarotene in a gel formulation in patients with mild to moderate nail psoriasis - parallel group comparison
    Medical condition: patients with mild to moderate nail psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003843-12 Sponsor Protocol Number: PP-CT01 Start Date*: 2017-01-16
    Sponsor Name:PILA PHARMA
    Full Title: A Single-dose dose escalation trial in a randomised, single-blind, placebo-controlled group-comparison design to investigate the safety and tolerability of XEN-D0501 in 24 patients with diabetes me...
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000573-72 Sponsor Protocol Number: ATOS-010 Start Date*: 2018-04-21
    Sponsor Name:Atossa Genetics Inc
    Full Title: Karma CREME-1: A double-blind, placebo-controlled, three-armed, pilot study of the effects, safety and tolerability of topical endoxifen in women within the Karma Cohort
    Medical condition: The mammographic density reduction in healthy women.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001216-29 Sponsor Protocol Number: PRCL-PoC Start Date*: 2018-09-11
    Sponsor Name:PRCL Research Inc.
    Full Title: A Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of PRCL-02 in Patients with Moderate to Severe Chronic Plaque Psoriasis
    Medical condition: Patients with moderate to severe chronic plaque psoriasis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-013671-21 Sponsor Protocol Number: V111_02 Start Date*: 2009-08-27
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Egg-Derived, Inactivated Novel Swine O...
    Medical condition: Pandemic influenza
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004979-35 Sponsor Protocol Number: 05-FOR-01 SE Start Date*: 2006-11-27
    Sponsor Name:Andi - Ventis
    Full Title: A RANDOMISED, FOUR WAY CROSS-OVER STUDY TO ASSESS BRONCHODILATION, SAFETY AND TOLERABILITY OF NEW GENERIC DRY POWDER FORMOTEROL FORMULATIONS GIVEN AS CUMULATIVE DOSES FROM A NOVEL DRY POWDER INHALE...
    Medical condition: reversible mild asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-003058-26 Sponsor Protocol Number: ModAll-Der/07 Start Date*: 2007-07-17
    Sponsor Name:LOFARMA
    Full Title: Pilot study on tolerability of specific immunotherapywith injective allergoid adsorbed on calcium phosphate in patients with respiratory allergy to house dust mite.
    Medical condition: allergic rhinoconjunctivitis with or without asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039085 Rhinitis allergic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006148-20 Sponsor Protocol Number: 071-005 Start Date*: 2009-01-07
    Sponsor Name:GALENpharma GmbH
    Full Title: A vehicle-controlled, investigator-blinded intraindividual comparison to evaluate the safety, tolerability and efficacy of Momegalen rich cream and ointment in patients with hand and foot eczema an...
    Medical condition: hand and foot eczema, mild to moderate psoriasis vulgaris
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 09:54:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA